In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints...
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy...
Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount.
Recent turmoil in the financial sector, renewed recession worries, and the Fed’s continued rate hikes paint an unfavorable picture for the stock market and economy. Amid this, long-term investors could...
